The results from Annexon Biosciences‘ ongoing proof-of-concept clinical trial of ANX1502, its novel treatment candidate for cold agglutinin disease (CAD), are now expected in early 2025, the company has announced. That trial is testing a new tablet formulation of the oral therapy in people with CAD. Earlier this…
News
Treatment with rituximab — commonly used off-label for cold agglutinin disease (CAD) — was reported to successfully resolve a serious case of CAD secondary to an Epstein-Barr virus (EBV) infection and potential contraceptive pill toxicity in a young woman in Europe. The woman had developed severe jaundice and liver…
Establishing a diagnosis of autoimmune hemolytic anemia (AIHA), a group of conditions including cold agglutinin disease (CAD), is sometimes difficult, due to the high variability in signs and symptoms and the possibility of a secondary cause, a review study showed. “Additionally, therapy is poorly evidence-based and mainly funded on…
Zydus Lifesciences’ desidustat eases the anemia and red blood cell destruction that mark autoimmune hemolytic anemia, or AIHA, a group of autoimmune conditions that includes cold agglutinin disease (CAD), a study in a mouse model has found. The oral therapy was shown to stimulate red blood cell production…
Parsaclisib, an experimental oral therapy from Incyte, safely and effectively increased levels of hemoglobin in about half of people with cold agglutinin disease (CAD) in a small Phase 2 clinical trial, a study shows. Data from the study (NCT03538041), which included people with other forms of autoimmune…
Restarting Enjaymo (sutimlimab) after stopping it for up to four months was generally safe and brought blood markers of cold agglutinin disease (CAD) back to levels before its cessation. These are the findings of a Japanese open-label extension (OLE) study wherein seven CAD patients who completed one of…
Recordati agreed to acquire the global rights to Enjaymo (sutimlimab), the only approved targeted therapy for cold agglutinin disease (CAD), from Sanofi. “With a strong clinical profile and as the only product approved for the treatment of CAD, Enjaymo addresses a serious unmet medical need for patients…
Researchers have developed an artificial intelligence (AI)-based model designed to identify existing medicines that could be repurposed to treat rare conditions such as cold agglutinin disease (CAD). The model, called TxGNN, was able to identify possible therapeutic candidates for more than 17,000 conditions in a study, and researchers believe…
How childhood autoimmune hemolytic anemia (AIHA) — a group of rare conditions that includes cold agglutinin disease (CAD) — is defined and classified varies widely, as does the approach to care for children with hard-to-treat disease, a review study shows. “Standardized definitions and classifications are needed to guide collaborative efforts…
The detection of cold agglutinins, the self-reactive antibodies that drive cold agglutinin disease (CAD), was crucial for the correct diagnosis and management of anemia — lower than normal levels of red blood cells or hemoglobin — in a 37-year-old man with several traumatic injuries after a motorcycle accident, according…
Recent Posts
- Post-exertional malaise leads to a cycle of crashes and comebacks
- Enjaymo provides lasting CAD control even with fewer doses: Study
- Being vigilant during transfusions brings me a vital victory
- Rituximab helps treat CAD linked to long-term immunosuppression: Case
- With my health from CAD steadily declining, I call in the cavalry, part 3
- Rituximab effective in rare dual autoimmune blood disorder case
- Unexplained anemia in seniors may signal autoimmune disease CAD
- With my health from CAD steadily declining, I call in the cavalry, part 2
- FDA fast-tracks potential new option for autoimmune blood diseases
- Long-term Enjaymo use shows favorable outcomes in CAD: Study